Heart in Diabetes 9th Annual Heart in Diabetes Conference 2025

Description

+ Include: 72 Videos (.mp4) + 72 Audios (.mp3) + 72 Subtitles (.vtt) + 57 PDFs, size: 32.09 GB

+ Target Audience: cardiologists, endocrinologists, and nephrologists

+ Sample video: contact me for sample video

+ Information:

1. Overview

The Heart in Diabetes 9th Annual Conference 2025 provides a comprehensive clinical exploration of the intersection between cardiovascular, renal, and metabolic diseases. The program delivers expert insights into managing resistant hypertension, chronic kidney disease, heart failure, obesity, and dyslipidemia, emphasizing the latest pharmacological advancements such as GLP-1 receptor agonists, SGLT2 inhibitors, and novel lipid-lowering therapies.

Course Date: 2025

2. Learning Objectives

• Evaluate the pathophysiology and clinical management of cardiorenal metabolic diseases, including resistant hypertension and diabetic cardiomyopathy.

• Implement guideline-directed medical therapies using GLP-1 RAs, SGLT2 inhibitors, and novel MRAs to optimize cardio-renal protection in patients with diabetes.

• Analyze the systemic impact of sleep disorders, hypercortisolism, and women-specific risk factors on cardiovascular and metabolic health.

• Assess the latest cardiovascular outcome trials (CVOTs) and integrate emerging lipid-lowering treatments targeting ApoB and CETP into clinical practice.

• Apply digital health technologies, intensive lifestyle interventions, and multidisciplinary approaches to manage complex cases involving obesity and heart failure.

3. Target Audience

Best for cardiologists, endocrinologists, and nephrologists who want updates on cardiorenal metabolic therapies, clinical trials, and obesity.

4. Topics

1. Day 1 01 Epidemiology and Pathophysiology of Resistant Hypertension and CKD Treatment

2. Day 1 02 Management of Chronic Kidney Disease With or Without Albuminuria

3. Day 1 03 Emerging Approaches to the Treatment of Resistant Hypertension

4. Day 1 04 Case Presentation – Treatment Resistant Hypertension

5. Day 1 05 Cortisol – Impact on Endocrinology & Metabolism

6. Day 1 06 Cortisol’s Impact on the Kidney-BP-Bone

7. Day 1 07 Cardiovascular Implications of Hypercortisolism

8. Day 1 08 Panel Discussion and Q&A – Cortisol & Cardiorenalmetabolic Diseases

9. Day 1 09 MASLD and MASH – Pathophysiology, Diagnosis and Management

10. Day 1 10 Sleep Health – Implications for Obesity and Diabetes Risk

11. Day 1 11 Sleep and Cardiovascular Risk

12. Day 1 12 Panel Discussion and Q&A – Sleep Disorders in Cardiometabolism

13. Day 1 13 Prediabetes – What’s a Clinician to Do

14. Day 1 14 Unraveling the Connection – Diabetes and Dementia

15. Day 1 15 Pulmonary Disorders in Diabetes – Implications for Heart Disease

16. Day 1 16 Diabetes and Cardiovascular Disease in Older Adults

17. Day 1 17 Panel Discussion and Q&A – Diabetes Comorbidities

18. Day 1 18 Implementing Guideline-Directed Medical Therapy – Stakeholder-Identified Barriers and Facilitators

19. Day 1 19 Population Health Approaches to Accelerate the Prevention of CVD – Moving from Action to Impact

20. Day 1 20 Panel Discussion and Q&A – Implementation Science in Practice

21. Day 1 21 Dyslipidemia in Women Across a Lifetime Approach to Management

22. Day 1 22 Sex Hormones and Anthropometric Measures & Heart Failure Risk in Women

23. Day 1 23 Panel Discussion and Q&A – Women’s Health

24. Day 1 24 Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone or In Combination With SGLT2 Inhibit…

25. Day 1 25 Optimal Strategy for Heart Failure Screening Among Adults With Diabetes Without ASCVD – A Pooled Cohort Analysis

26. Day 1 26 Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibro…

27. Day 1 27 Accelerated Risk-Based Implementation of Guideline-Directed Medical Therapy for Chronic Kidney Disease

28. Day 1 28 Panel Discussion and Q&A – Circulation

29. Day 2 01 Current Trends in Epidemiology of Heart Failure – USA

30. Day 2 02 Diabetic Cardiomyopathy – Mechanisms and Future Directions

31. Day 2 03 Bromocriptine in the Treatment of Peripartum Cardiomyopathy – Is It Ready for Prime Time

32. Day 2 04 Proper Medical Management of HFpEF in 2025

33. Day 2 05 Panel Discussion and Q&A – Heart Failure – The Now & The New

34. Day 2 06 GLP1-RA, Obesity & Diabetes – Mechanisms of Cardiovascular Protection

35. Day 2 07 Cardio-Kidney Protection With Incretin Therapies

36. Day 2 08 Incretins – Today and Tomorrow

37. Day 2 09 Panel Discussion and Q&A – Current & Future Role of Incretin Therapy

38. Day 2 10 Diabetes and Cardiovascular Disease – The Evolution of CV Outcomes Assessment of Antihyperglycemic Medications

39. Day 2 11 My Personal Journey to HoFH Diagnosis

40. Day 2 12 From Rare to the Very Common – Role of Genetics in Lipid Disorders

41. Day 2 13 CETPi – Where Might They Fit Into Clinical Practice

42. Day 2 14 Using ApoB in Clinical Practice – From Risk Assessment to Treatment Targets

43. Day 2 15 Obesity and Dyslipidemia – Can We Finally Break the Cycle With Dual Agonists

44. Day 2 16 The Epidemiology and Pathophysiology of Cardio-Kidney-Metabolic Diseases

45. Day 2 17 Unmet Needs in CKD in T1D and Challenges in CKD Beyond Diabetes

46. Day 2 18 Finerenone Across the Stages of Heart Failure – From Prevention to Treatment

47. Day 2 19 Panel Discussion and Q&A – Cardio-Renal Protection in CKM Diseases

48. Day 2 20 Digital Health Technologies for Cardiometabolic Disease & Diabetes

49. Day 2 21 Food Is Medicine Strategies for Nutrition Security & Cardiometabolic Health Equity – JACC State-of-the-Art Review

50. Day 2 22 Intensive Lifestyle Intervention, Cardiac Biomarkers, and Cardiovascular Outcomes in Diabetes – The Look AHEAD Cardiac…

51. Day 2 23 Racial Differences in Diabetic Cardiomyopathy – Results From the Phase 3 Randomized Controlled ARISE-HF Study

52. Day 2 24 Panel Discussion and Q&A – JACC

53. Day 2 25 Technology in the Management of Diabetes – Addressing Its Role in Comorbidities

54. Day 2 26 SGLT2 Inhibitors – Reconsidering, Repurposing, Reimagining

55. Day 2 27 Panel Discussion and Q&A – Diabetes Management & Technology

56. Day 3 01 Management of Complex Cases – Obesity and Heart Failure

57. Day 3 02 The Edema Dilemma – A Case of Diabetes Mellitus, Heart Failure With Preserved Ejection Fraction, Obesity, Chronic Kidne…

58. Day 3 03 CRM Management of Complex Cases

59. Day 3 04 The Lancet Commission on Obesity

60. Day 3 05 Obesity – Role of Medical Management

61. Day 3 06 Management of Obesity Addressing Lean Mass Preservation

62. Day 3 07 Panel Discussion and Q&A – Obesity

63. Day 3 08 Do ACEiARB Still Have a Role in the Era of SGLT2, MRA and GLP1A

64. Day 3 09 The Role of Diastolic & Pulse Pressure in CKD & CVD – Management Considerations

65. Day 3 10 Aldosterone – The Forgotten Hormone in Hypertension

66. Day 3 11 Panel Discussion and Q&A – The Kidney and Hypertension

67. Day 3 12 Combination Treatment to Improve Heart and Kidney Outcomes in Diabetic Kidney Disease

68. Day 3 13 The Latest Heart Disease & Stroke Statistics – US & Global Data from the American Heart Association

69. Day 3 14 Appropriate Cardiac Intervention in the Diabetes Cardiorenal & Metabolic Medicine Patient

70. Day 3 15 Serum Lipoproteins & Coronary Atherosclerosis in Asymptomatic U.S. Adults Without Traditional Risk Factors

71. Day 3 16 Cardiovascular Outcome Trials Update

72. Day 3 17 Panel Discussion and Q&A – ASCVD